Health Care • Biotechnology: Commercial Physical & Biological Resarch
$2.91 ▼ -0.12
(-3.96%)
MKT CAP: $3.9M • VOL: 47.3K
52W L $3 52W H $81
BIAF // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $6.2M | $9.4M | $2.5M |
| YoY Revenue Growth % | -34.2% | +269.7% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$10.6M | -$9.0M | -$8.0M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$14.9M | -$9.0M | -$7.9M |
| EBITDA (Normalized) | -$10.5M | -$8.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$9.3M | -$7.3M | -$6.0M |
| Capital Expenditures (CapEx) | $60.6K | $79.1K | — |
| Free Cash Flow (FCF) | -$9.4M | -$7.3M | -$6.0M |
| FCF Margin % | -80.0% | -78.4% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $6.4M | $1.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $7.3M | $2.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BIAF.